Use of First-Line Oral Analgesics during and after COVID-19: Results from a Survey on a Sample of Italian 696 COVID-19 Survivors with Post-Acute Symptoms

Author:

Galluzzo Vincenzo1ORCID,Zazzara Maria Beatrice1,Ciciarello Francesca1,Tosato Matteo1ORCID,Bizzarro Alessandra1,Paglionico Annamaria1,Varriano Valentina1,Gremese Elisa1,Calvani Riccardo12ORCID,Landi Francesco12

Affiliation:

1. Department of Geriatrics, Orthopedics and Rheumatology, Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, 00168 Rome, Italy

2. Department of Geriatrics and Orthopedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

Abstract

Background—Analgesics could be used to manage painful symptoms during and after COVID-19. Materials and methods—Persistence of painful symptoms was assessed during and after COVID-19 in a sample of patients admitted to a post-acute COVID-19 outpatient service in Rome, Italy. Data on type and frequency of use of first-line analgesics were collected. Pain severity was evaluated with a numeric rating scale (NRS) from 0 to 10. Results—Mean age of 696 participants was 57.1 ± 20.3 years and 61.7% were women. During COVID-19, the most prevalent symptoms were fever, fatigue, arthralgia, myalgia and headache. Acetaminophen was used by 40% of the sample. Only 6.7% needed to continue analgesic therapy after COVID-19. Frequent causes of analgesics consumption were persistent arthralgia and myalgia. The most common analgesics used amongst those who continued taking analgesics in the post-acute phase of COVID-19 were the following: acetaminophen (31%), ibuprofen (31%) and other non-steroidal anti-inflammatory drug (NSAID) (29.5%); in older subjects the most common analgesic used was acetaminophen (54%). Most of the subjects in this group said there was an improvement in pain perception after taking analgesic therapy (84%). Conclusions—Use of analgesics in the post-acute COVID-19 is common in subjects with persistent arthralgia and myalgia, and common analgesics were acetaminophen and ibuprofen. Further research on the safety and efficacy of those medications in COVID-19 is warranted.

Funder

Angelini Pharma, Fondazione Angelini, Fondazione Memmo, Danone, Nutricia

Publisher

MDPI AG

Subject

General Medicine

Reference50 articles.

1. COVID-19 diagnosis and management: A comprehensive review;Pascarella;J. Intern. Med.,2020

2. Severe organising pneumonia following COVID-19;Roller;Thorax,2021

3. Severe COVID-19 pneumonia: Pathogenesis and clinical management;Attaway;BMJ,2021

4. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment;Parasher;Postgrad. Med. J.,2020

5. Gemelli Against COVID-19 Post-Acute Care Study Group (2020). Post-COVID-19 global health strategies: The need for an interdisciplinary approach. Aging Clin. Exp. Res., 32, 1613–1620.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3